In April 2024 Citeline’s Scrip publication reviewed the internal and external R&D inputs of the top 15 companies by sales of prescription and over-the-counter drugs in 2023. This analysis reve
Known for its blockbusters for infectious disease including Biktarvy (bictegravir/emtricitabine/tenofovir) for HIV and COVID-19 therapeutic Veklury (remdesivir), Gilead Sciences, Inc. is intending t
While Gilead Sciences, Inc. , AstraZeneca PLC and Pfizer Inc. have spent billions acquiring expertise in antibody-drug conjugates, Merck & Co., Inc. has trodden a different path. Two low-key de
Gilead Sciences, Inc. unveiled new and updated positive data from a Phase II trial of Trodelvy (sacituzumab govitecan-hziy) in metastatic urothelial cancer (mUC) on 17 February, part of a dataset the